Despite the widespread occurrence of bone metastasis, reliable fi gures for the prevalence or incidence of patients with bone metastases remain elusive. 1 It has been estimated that up to 70% of patients with advanced breast or prostate cancer and 15% to 30% of patients with lung cancer will develop bone metastases. 2 In the United States alone, approximately 350,000 people who die annually from cancer will have bone metastases. 2 Multiple myeloma, occurring less frequently than the previously mentioned cancers, is a cancer of plasma cells and is frequently implicated in the development of widespread bony involvement.
Homeostasis of healthy bone is maintained by the opposing actions of osteoblasts and osteoclasts. The microenvironment created by constant bone resorption (osteoclasts) and formation (osteoblasts) creates a highly favorable environment as a site of metastases. Adhesive molecules manufactured by the tumor cells allow binding to marrow stromal cells and the bone matrix. 2 High blood fl ow through the red marrow of bone also creates ample opportunity for metastatic cells to come in contact with this new environment. 3 Consequences from bone metastases range from bone pain and fractures to hypercalcemia and spinal cord compression. Historically, bone metastases have been classifi ed as either strictly osteolytic (bone destructing) or osteoblastic (bone forming). The complication encountered is often a product of the type of bone lesion, which is most commonly subject to the type of cancer involved. For example, bone metastases secondary to multiple myeloma are purely osteolytic lesions that result in an unbalanced erosion of the bone. 2 With the exception of multiple myeloma, most bone metastases contain features of both lytic and blastic involvement. 3 It is important to note that clinical trials investigating treatment options for metastatic bone disease use a composite endpoint termed skeletal-related events. Bone metastases are highly correlated with skeletal-related events, hence the use of the composite endpoint in clinical trials. Abstract: Metastases to the bone are a frequent complication of advanced cancer. Bone metastases have been linked to skeletal-related events, which is the composite endpoint used in clinical trials evaluating therapy to minimize these complications. This article discusses bisphosphonates, which are the historical standard for the prevention of skeletal-related events in patients with metastases from solid tumors and multiple myeloma, and denosumab, which is the fi rst Food and Drug Administration-approved receptor activator of nuclear factor kappa-␤ ligand (RANKL) inhibitor.
■ pharmacology update cal perspective of the bisphosphonates and an update on an agent that was Food and Drug Administration (FDA) approved within the past year.
BISPHOSPHONATES
Bisphosphonates are absorbed primarily by the bones because the side chains of these molecules have a high affi nity for calcium. Once integrated into the bone, bisphosphonates may either induce apoptosis of osteoclasts or interfere with the attachment, differentiation, and survival of osteoclasts. 4 The 2 bisphosphonates currently approved by the FDA for the prevention of skeletal-related events in the United States are pamidronate and zoledronic acid. A recent review summarized the clinical data leading to the approval of these 2 agents. 5 Nephrotoxicity is a common adverse event that is reported to occur in approximately 7% of patients receiving either pamidronate or zoledronic acid. 6 Dose adjustments are recommended for both agents in patients experiencing renal dysfunction at baseline, as well as interruptions of therapy in patients experiencing drastic increases in serum creatinine. Osteonecrosis of the jaw is a rare but serious complication associated with the use of bisphophonates. A recent metaanalysis, which pooled the 3 major identical clinical trials comparing zoledronic acid to denosumab in the prevention of skeletal-related events, determined that osteonecrosis of the jaw occurred in 1.3% of patients receiving zoledronic acid compared with 1.8% of those treated with denosumab (Pϭ.13). 7 A separate retrospective analysis of multiple myeloma patients reported that 11% of patients receiving a bisphosphonate developed osteonecrosis of the jaw. 8 The authors concluded that when individual bisphophonates were compared, zoledronic acid was associated with a 9.5-fold greater risk of osteonecrosis of the jaw compared with pamidronate (Pϭ.042). 8 Other toxicities may include fl u-like symptoms, myalgia, and arthralgia (Table) .
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DENOSUMAB
Denosumab is a human monoclonal antibody that targets the receptor activator of nuclear factor kappa-␤ ligand (RANKL). In patients with metastatic bone disease from solid tumors, there is excess osteoclastic activity that is mediated by RANKL. This, in turn, results in changes of bone architecture potentially leading to skeletal-related events. 10 Denosumab binds to RANKL, thereby inhibiting osteoclastmediated bone destruction. Denosumab is marketed as both Xgeva (Amgen, Thousand Oaks, California) and Prolia (Amgen) in the United States. It is important to note that the 2 marketed products have received different FDA-approved indications and are not interchangeable. For the purpose of this discussion, all indications in this article refer to Xgeva, which is currently approved by the FDA for the prevention of skeletal-related events in patients with bone metastases from solid tumors but not from multiple myeloma.
Three phase III trials have led to the approval of deno- The primary endpoint in all 3 trials was a noninferiority comparison of the time to the fi rst on-study skeletal-related event. A skeletal-related event was defi ned as pathologic fracture (excluding major trauma), radiation therapy to bone, surgery to bone, or spinal cord compression. If noninferiority was demonstrated, then secondary effi cacy endpoints for superiority were assessed for the time to fi rst on-study skeletal-related event and time to fi rst and subsequent on-study skeletal-related event.
Stopeck et al 11 compared the above regimens for the treatment of bone metastases in patients with breast cancer. Denosumab delayed time to fi rst on-study skeletal-related event by 18% (20.6 months for denosumab vs 16.3 months for zoledronic acid; PϽ.001 for noninferiority, Pϭ.01 for superiority) and was also found to be superior in regard to time to fi rst and subsequent on-study skeletal-related event (Pϭ.001). 11 Fizazi et al 12 compared the same regimens for the treatment of bone metastases in men with castration-resistant prostate cancer. Denosumab delayed time to fi rst on-study skeletal-related event by 18% (median, 20.7 months for denosumab vs 17.1 months for zoledronic acid; Pϭ.0002 for noninferiority, Pϭ.008 for superiority) and was found to be superior for time to fi rst and subsequent on-study skeletalrelated event (Pϭ.008). 12 Henry et al 13 compared denosumab to zoledronic acid for the treatment of bone metastases in patients with advanced cancer or multiple myeloma, excluding breast and prostate cancer. Denosumab delayed time to fi rst on-study skeletal-related event by 16% but was not found to be superior for time to fi rst and subsequent on-study skeletal-related event (Pϭ.0007 for noninferiority, Pϭ.06 for superiority). Overall survival and disease progression were similar in both study groups. However, an ad hoc analysis of overall survival found that patients with multiple myeloma had a two-fold higher risk of death in the denosumab arm. 13 Adverse effects were similar in both study groups, including the risk for osteonecrosis of the jaw. However, more patients in the denosumab group experienced hypocalcemia.
The most common adverse effects associated with denosumab use include fatigue/ asthenia, hypophosphatemia, and nausea. Patients taking this medication need to have serum magnesium, phosphorus, and calcium levels checked monthly (Table) . The risk of hypocalcemia is increased in patients with a creatinine clearance Ͻ30 mL/minute or those on dialysis. All patients should receive calcium and vitamin D supplementation. When initiating denosumab therapy, hypocalcemia should be corrected fi rst. 14 None of the bone-modifying agents currently available have demonstrated a survival advantage over the others; therefore, no consensus exists for a treatment pathway. Zoledronic acid has largely supplanted pamidronate in the clinical setting because infusion time is greatly reduced with zoledronic acid. Both pamidronate and zoledronic acid carry a risk of nephrotoxicity and need to be adjusted in renal dysfunction.
Potential advantages of denosumab are that it does not require adjustment in renal impairment and it is easier to administer relative to the other bone-modifying agents (Table) . In a patient with renal impairment, denosumab may provide a unique advantage over the others, although the risk of hypocalcemia may be increased in the setting of renal dysfunction. All of these agents require a baseline and regular dental examination to prevent patients with poor dentition from receiving an agent that may cause osteonecrosis of the jaw. The risks of osteonecrosis of the jaw appear to be similar between zoledronic acid and denosumab, but differences among the available bisphosphonates are less clear.
THE BOTTOM LINE
• Skeletal-related events occur most frequently in patients with breast, prostate, and multiple myeloma.
• Skeletal-related events, which have been closely linked to bone metastases, are usually defi ned as pathologic fractures, spinal cord compression, surgery for the prevention or treatment of fractures or cord compression, or radiation therapy for bone pain.
• Bisphosphonates are the current standard treatment for the prevention of skeletal-related events from solid tumors and multiple myeloma.
• Denosumab was recently approved by the Food and Drug Administration as the fi rst receptor activator of nuclear factor kappa-␤ ligand inhibitor for the prevention of skeletal-related events from solid tumors but not from multiple myeloma.
